NIPD Genetics Raises €2.5M to Fund Development of Noninvasive Down Syndrome Dx
October 06, 2011
NIPD Genetics Raises €2.5M to Fund Development of Noninvasive Down Syndrome Dx
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Cyprus' NIPD Genetics Validates Updated Trisomy 21 Assay; Eyes 2013 Launch for Testing Services
November 29, 2012 / PCR Insider - Cypriot Group Develops Non-Invasive, Prenatal Down Syndrome Dx; Creates Startup to Market Test
March 10, 2011 / PCR Insider - Castle Biosciences to Add to Orphan Cancer Dx Menu with IU Thymoma Gene License
January 26, 2012 / PCR Insider - Hologic Women's Health Deal with Quest Viewed as Loss for Qiagen, Particularly on HPV Front
June 13, 2013 / PCR Insider - Diagnoplex Using $1.4M Influx to Prep Blood-based Colorectal Cancer Test for CE Mark, 2014 Launch
June 13, 2013 / PCR Insider